Equity
€1.2m ▲ 3.6%
PHARMALLIANCE has made a profit in every financial year since 2007.
PHARMALLIANCE
Lifetime
19 annual accounts with figures on one time axis, 20 filings since 2006peak €1.2m (2025)
€1.2m▲ 37.6%
peak €318,693 (2018)
€43,298▼ 30.8%
peak €1.2m (2025)
€1.2m▲ 3.6%
€5.1m▼ 2.8%
peak 13.5 FTE (2025)
13.5 FTE▲ 6.3%
Board3 names since 2016
3 directorsBLUESTONE and 2 others
Owners4 names in the annual accounts
40%LENANS and 2 others
Documentsfilings and deeds
22-08-202622 days late
2025financial year
Gross margin from €886,497 to €1.2mResult from €62,582 to €43,298Purpose change · Amendment of the articles 15-01Cash from €127,884 to €68,305
Key points
from the 2025 annual accountsChecked score
63
Healthy
Financially stronger than 32% of small companies in retail trade (NACE 47)
Probability in this band: 0.55% to 1.5%
Bankruptcy probability within 12 months
1.3% Low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.4% across 3,697 companies (NACE 47, small).
About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 1.9%
01-2025: 1.1%▼ -0.8 percentage points vs 12-2024
02-2025: 1.1%● unchanged vs 01-2025
03-2025: 1.1%● unchanged vs 02-2025
04-2025: 1.1%● unchanged vs 03-2025lowest value
05-2025: 1.1%● unchanged vs 04-2025
06-2025: 1.1%● unchanged vs 05-2025
07-2025: 1.1%● unchanged vs 06-2025
08-2025: 1.1%● unchanged vs 07-2025
09-2025: 1.2%▲ +0.1 percentage points vs 08-2025
10-2025: 1.5%▲ +0.3 percentage points vs 09-2025
11-2025: 1.4%▼ -0.1 percentage points vs 10-2025
12-2025: 1.4%● unchanged vs 11-2025
01-2026: 1.4%● unchanged vs 12-2025
02-2026: 1.4%● unchanged vs 01-2026
03-2026: 1.3%▼ -0.1 percentage points vs 02-2026
04-2026: 1.4%▲ +0.1 percentage points vs 03-2026
05-2026: 1.4%● unchanged vs 04-2026
06-2026: 1.4%● unchanged vs 05-2026
07-2026: 1.5%▲ +0.1 percentage points vs 06-2026
08-2026: 2.3%▲ +0.8 percentage points vs 07-2026highest value
09-2026: 1.3%▼ -1.0 percentage point vs 08-2026
10-2026: 1.3%● unchanged vs 09-2026
11-2026: 1.3%● unchanged vs 10-2026
Financial strengthWeak
Score breakdown
raises risk
Liquidity: current ratio 0.47, cash €68,305
Last filed accounts filed 22 days late; 2 of the last 3 accounts late
Size: 13.5 FTE, total assets €6.4m
lowers risk
Founded in 2004
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, small). It does better than 35% of them on solvency, 23% on liquidity, 21% on profitability and 51% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the low class on 30-06-2025, 0.8% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 4,685 companies had the same profile as PHARMALLIANCE has now. Each dot stands for 12 companies, two years later.
97.0%
were still trading
1.9%
stopped another way
1.1%
went bankrupt
That fits the bankruptcy probability of PHARMALLIANCE itself: 1.3% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 4,685 companies, not a prediction for PHARMALLIANCE. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €75,000 on 30-day terms is acceptable
Liquidity is insufficient, with a current ratio of 0.47 (0.52 in 2024), below 1. Short-term debt is 53.7% and cash 1.1% of total assets. 80.4% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises risk
raises risk · 2025 accounts filed 22 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 22-08-2026, 22 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
22 days late
2024
82 days late
2024
32 days late
2023
30 days late
2022
3 days late
2021
2 days late
2020
16 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 27 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsWhere today falls in the filing period
09-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
- LENANS 40%score 85equity €719,922 (2025) · 2025 annual accounts of LENANS
- BLUESTONE 18%score 78equity €2.5m (2025) · 2025 annual accounts of BLUESTONE
- SWAKOPMUND 18%score 94equity €1.4m (2025) · 2025 annual accounts of SWAKOPMUND
Shares in 2 companies, DELTAPHAR and PHARMACIE de BARRY
Board & ownershipRecent changes
Purpose change · Amendment of the articles
“L'exploitation d'officines pharmaceutiques dans le respect des règles édictées par l'Ordre des Pharmaciens,et…” (deed in French) · General meeting of 27-12-2024 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0867465852
3 directors reappointed
LENANS (managing director), Jean-Claude Mahieu and BLUESTONE (managing director) · Permanent representatives: Nathalie Mahieu and Paul Ransart · General meeting of 02-11-2022 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| PHARMALLIANCE Lasne | €6.4m | €1.2m | 19.6% | 13.5 |
| KING KONG Bertem | €4.2m | €1.5m | 41.3% | 10.8 |
| Apotheek Olyslager-Snoeckx Brasschaat | €4.9m | €1.7m | 41.3% | 9.9 |
| Europhar Genappe | €3.5m | €1.6m | 6.6% | 16.1 |
| APOTHEEK PEETERS - PETIT Maasmechelen | €5.0m | €1.1m | 20.3% | 14.2 |
| WE-PHARMA Huy | €4.5m | €1.2m | 30.7% | 19.6 |
| LES PHARMACIES RURALES Celles (lez-Tournai) | €5.9m | €1.5m | 3.3% | 19.6 |
These companies have the same main activity as PHARMALLIANCE: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €3.5m and €5.9m, founded between 1987 and 2009.
Official details
Source: KBO- Status
- Active since 28-09-2004Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Establishment units
- 2.142.397.2301160 Auderghem, since 24-09-2004
- 2.154.771.7577940 Brugelette, since 01-01-2006and 2 others
- Financial year end
- 31 December
- Peppol
- Reachable since 24-11-2023
Annual accounts 2025
- ≈ €3.3mestimated
- €6.4m▼ 1.6%
- Employeeson 31-12-2025
- 16▼ 5.9%
- Filing
- Filed on 22-08-2026
Companies linked to PHARMALLIANCE
Insights on PHARMALLIANCE
PHARMALLIANCE has existed since 2004. The gross margin grew from €320,736 in 2007 to €1.2m in 2025 and staff from 4.8 to 13.5 full-time equivalents.
In June 2023, the Official Gazette published the appointment of BLUESTONE as managing director.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about PHARMALLIANCE
- What is the company number of PHARMALLIANCE?
- The company number of PHARMALLIANCE is 0867.465.852. The VAT number is the same number with BE in front: BE 0867.465.852.
- Where is PHARMALLIANCE based?
- The registered office is at Rue de la Bachée 84, 1380 Lasne.Company details
- What does PHARMALLIANCE do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of PHARMALLIANCE?
- PHARMALLIANCE is a public limited company (NV).
- When was PHARMALLIANCE founded?
- PHARMALLIANCE was founded on 28-09-2004.
- Is PHARMALLIANCE still active?
- Yes, PHARMALLIANCE is an active enterprise in the KBO register.
- How many employees does PHARMALLIANCE have?
- PHARMALLIANCE had an average of 13.5 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of PHARMALLIANCE?
- The turnover in financial year 2025 is ≈ €3.3m. This figure is estimated from the gross margin of €1.2m and 31 comparable companies (NACE 477). It probably lies between €2.4m and €4.6m.
- Is PHARMALLIANCE profitable?
- In financial year 2025, PHARMALLIANCE made a profit of €43,298.
- Where can I find the annual accounts of PHARMALLIANCE?
- PHARMALLIANCE filed 21 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of PHARMALLIANCE due?
- PHARMALLIANCE must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.